C O N F E R E N C E P R O G R A Mwww.personalizedmedicineconference.org

Personalized Medicine:The Time is Now

A Conference Hosted By

5th Annual Conference

November 18-19, 2009Joseph B. Martin Conference Centerat Harvard Medical School, Boston

HIGHLIGHTS FROM PAST CONFERENCES

3

November 18, 2009

Dear Colleague,

On behalf of the Organizing Committee we are pleased to welcome you to the 2009conference Personalized Medicine: The Time is Now. This is the fifth annual conferenceorganized under the auspices of the Partners HealthCare Center for Personalized GeneticMedicine (PCPGM). Partners HealthCare System has made a significant commitment toadvancing the cause of personalized medicine. PCPGM is doing that on many fronts; thismeeting is one of them.

We have always felt that making personalized medicine a reality would result in betteroutcomes for patients at a reduced cost of healthcare for society. Incorporating theprinciples of personalized medicine into healthcare requires the participation andcooperation of many sectors of our society. Our annual meetings, through the formalprogram and the informal interactions that will take place among and between participants,bring the critical stakeholders together to engage in discussions that will help advance themomentum of personalized medicine. The theme of this year’s meeting, The Time is Now, isintended to signal how much is already being done to apply the premises and principles ofpersonalized medicine in real ways in the care of patients. Just as important, it is intendedto remind everyone with a stake in personalized medicine that for all the progress that hasbeen made much more work needs to be done and that there should be no relaxing of theeffort and focus. We have added two new program elements this year that we hope willfurther advance that objective. One is to have an active electronic audience response systemin all of the sessions, to enable all attendees to indicate their perspectives on and opinionsabout the subjects under discussion. The other is to present, in modified Harvard BusinessSchool case study fashion, two examples of how personalized medicine is beingimplemented.

Attendees from our past conferences have enjoyed the diversity of attendees, speakers andpanelists that come to our meeting. It is a rich variety indeed and we encourage you to meetold friends and make many new ones.

PCPGM is pleased to have Harvard Business School and Harvard Medical School asco-hosts for the meeting. We extend special thanks to the Personalized Medicine Coalitionfor its collaboration on the conference in so many ways. And we deeply appreciate themembers of the Organizing Committee, the speakers, the panelists, the staff and ourgenerous sponsors for their vital contributions to the success of our meeting.

Sincerely,

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics andProfessor of Medicine, Harvard Medical School;Chair, Conference Organizing Committee

Scott T. Weiss, M.D., M.S.Interim Scientific DirectorPartners HealthCare Center forPersonalized Genetic Medicine;Professor of Medicine, Harvard Medical School

Thanks to Our SponsorsThis conference is organized by the Partners HealthCare Center for

Personalized Genetic Medicine and Harvard Business School in collaborationwith the Personalized Medicine Coalition. It is made possible by the

generous support of our sponsors.

GOLD

SILVER

4

5

BRONZE

CONTRIBUTING SPONSOR

6

Conference ProgramWednesday, November 18, 2009

7:00 a.m. Registration & Continental Breakfast

8:00 a.m. Welcome Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics,Professor of Medicine, Harvard Medical School

Opening Remarks Scott T. Weiss, M.D., M.S.Interim Scientific Director, Partners HealthCare Center forPersonalized Genetic Medicine, Professor of Medicine,Harvard Medical School

Gary Gottlieb, M.D., M.B.A.President, Brigham and Women’s Hospital,President & Chief Executive Officer-Designate,Partners HealthCare System

8:45 a.m. Panel: Success Stories in Moderator: Lawrence Lesko, Ph.D.Personalized Medicine Director of Clinical Pharmacology, CDER, FDA

Introducer: Felix W. Frueh, Ph.D.Vice President, R&D, Personalized Medicine,Medco Health Solutions, Inc.

Pierre CassigneulPresident & Chief Executive Officer, XDx

Richard DingVice President Theranostics, bioMerieux SA

Jon FriedenbergVice President, El Camino Hospital

Arlene Hughes, Ph.D.Genetics Therapy Area Head, GlaxoSmithKline

10:00 a.m. Networking Break

10:45 a.m. Electronic Medical Records & John Glaser, Ph.D.Personalized Medicine Vice President & Chief Information Officer,

Partners HealthCare System

Introducer: Jeffrey D. MillerManaging Partner, Versum Ventures

11:15 a.m. Panel: The Current Revolution Moderator: John Glaser, Ph.D.in Information Technology Vice President & Chief Information Officer,& Its Role in Personalized Partners HealthCare, SystemMedicine

Samuel J. AronsonExecutive Director of Information Technology,Partners HealthCare Center for Personalized Genetic Medicine

Brett J. Davis, M.B.A.Senior Director, Health Sciences Global Business Unit, Oracle

Lori Evans, M.P.H.Chief Executive Officer, ActiveHealth Community Solutions

Douglas J. Moeller, M.D.Medical Director, McKesson Health Solutions

12:30 p.m. Break - transition

7

1:00 p.m. Luncheon and Presentation of Brook ByersPersonalized Medicine Partner, Kleiner Perkins Caufield & ByersCoalition’s Fifth AnnualAward for Leadership Introduction: Edward Abrahams, Ph.D.in Personalized Medicine Executive Director, Personalized Medicine Coalition

Presentation:M. Kathleen Behrens, Ph.D.Founder, KEW Group

2:00 p.m. Table Discussions Convener: Rebecca RehmProgram Associate, Partners HealthCare Center for

See page 29 of the Program for details Personalized Genetic Medicine

3:00 p.m. Break - transition

3:15 p.m. Panel: Is Personalized Medicine Moderator: Susan DentzerGoing to Cost Too Much? Editor-In-Chief, Health Affairs

Introducer: Alfred A. Blum, Jr.Chief Development Officer, Partners HealthCare Center forPersonalized Genetic Medicine

Robert S. Epstein, M.D., M.S.Senior Vice President, Department of Medical & AnalyticalAffairs and Chief Medical Officer, Medco Health Solutions

John Fallon, M.D., M.B.A., FACPSenior Vice President, Chief Physician Executive,Blue Cross Blue Shield of Massachusetts

Sharon Levine, M.D.Associate Executive Director, The Permanente Medical Group

Lee Newcomer, M.D.Senior Vice President, Oncology, UnitedHealth Group

4:30 p.m. “Bringing Personalized Medicine Gerardo Jimenez-Sanchez, M.D., Ph.D.To Mexico: Local Perspectives & Founder Director, National Institute of Genomic Medicine,Global Challenges” Chairman,Working Party on Biotechnology,

Organisation for Economic Co-operation and Development

Introducer: Robert C. WellsHead, Biotechnology Unit, Science and Technology PolicyDivision, Directorate for Science, Technology and Industry,Organisation for Economic Co-operation and Development

5:00-6:30 p.m. Reception at Elements Café Host: Janice LarsonDevelopment Associate, Partners HealthCare Center forPersonalized Genetic Medicine

Conference ProgramWednesday, November 18, 2009

8

7:45 a.m. Registration & Continental Breakfast

8:30 a.m. Keynote: UK’s Approach Sir Michael Rawlins, M.D., FMedScito Personalized Medicine Chairman, National Institute for Health and Clinical Excellence

Introducer: Katherine Johansen, Ph.D.Senior Scientist, Genetics and Molecular Medicine, AmericanMedical Association

9:00 a.m. Where Are We inPersonalized Medicine?

Regulatory & Financial Philip C.M. Ma, Ph.D.Perspective Director, McKinsey & Company

Introducer: Jeffrey Elton, Ph.D.Founder, KEW Group

Legislative Perspective Nick LittlefieldPartner, Foley Hoag

Sheila WalcoffPartner, McDermott Will & Emery

Introducer: Joseph L. FaberCo-founder and Principal, Faber Daeufer & Roseberg

Predicting the Future Alison AyersVice President, Oncology WorldWide,Commercial Development, Pfizer

Introducer: Hakan Sakul, Ph.D.Senior Director and Global Head of Diagnostics, Translationaland Molecular Medicine Group Worldwide Development, PfizerGlobal Research & Development

10:15 a.m. Networking Break

10:45 a.m. Panel: How Can Business Moderator: Frank Douglas, Ph.D., M.D.Accelerate Personalized President & Chief Executive Officer, Austen BioInnovationMedicine? Institute, Senior Partner, PureTech Ventures

Introducer: Sandra Glucksmann, Ph.D.Senior Vice President of Research and Business Operations,Cerulean Pharmaceuticals

Noubar Afeyan, Ph.D.Managing Partner & Chief Executive Officer, Flagship Ventures

G. Steven BurrillChief Executive Officer, Burrill & Company

David P. KingPresident & Chief Executive Officer,Laboratory Corporation of America

Mark LevinPartner, Third Rock Ventures

12:00 p.m. Bag Lunch

Conference ProgramThursday, November 19, 2009

9

1:00 p.m. Interactive Case Studies on Moderators:Business Strategies for Richard Hamermesh, D.B.A.Personalized Medicine MBA Class of 1961 Professor of Management Practice,

Harvard Business SchoolCase 1: Managing Drugs on theForefront of Personalized Medicine: Mara G. AspinallThe Story of the Colorectal Cancer President & Chief Executive Officer, On-Q-ityDrugs Erbitux and Vectibix

Introducer: Thomas J. MillerCase 2: The Explosion of Genetic Chief Executive Officer, Division Workflow & Solutions,Testing: What Opportunities and Siemens AG, Sector HealthcareChallenges Await?

Discussants:Alison AyersVice President, Oncology WorldWide,Commercial Development, Pfizer

Stephen Eck, M.D., Ph.D.Vice President, Translational Medicine & Pharmacogenomics,Eli Lilly

2:30 p.m. Panel: Who Will Benefit from Moderator: Linda AveyPersonalized Medicine? Founder, Brainstorm Research Foundation

Introducer: Nancy Simonian, M.D.Chief Medical Officer, Millennium: The Takeda Oncology Company

Daniel A. Haber, M.D., Ph.D.Director, Cancer Center, Massachusetts GeneralHospital, Harvard Medical School

Marc S. Sabatine, M.D., M.P.H.Associate Physician, Assistant Professor of Medicine,Brigham and Women’s Hospital, Harvard Medical School

Troyen A. Brennan, M.D.Executive Vice President and Chief Medical Officer, CVS Caremark

Vance Vanier, M.D.Chief Medical Officer, Navigenics

3:45 p.m. Closing Remarks Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics,Professor of Medicine, Harvard Medical School

Conference ProgramThursday, November 19, 2009

10

Edward Abrahams, Ph.D.Edward Abrahams, Ph.D., is executivedirector of the Personalized MedicineCoalition (PMC). Representing a broadspectrum of academic, industrial,patient, provider and payer communi-ties, PMC seeks to advance the under-standing and adoption of personalizedmedicine concepts and products for thebenefit of patients. It has grown from its

original 18 founding members in November 2004 to over160 today.Previously Dr. Abrahams was Executive Director of the

Pennsylvania Biotechnology Association, where he spear-headed the successful effort that led to the Commonwealthof Pennsylvania’s investment of $200 million to commer-cialize biotechnology in the state. Earlier he had beenAssistant Vice President for Federal Relations at theUniversity of Pennsylvania and held a senior administrativeposition at Brown University.Dr. Abrahams worked for seven years for the U.S.

Congress, including as a legislative assistant to SenatorLloyd Bentsen, an economist for the Joint EconomicCommittee under the chairmanship of Representative LeeHamilton, and as a AAAS Congressional Fellow for theHouse Committee on the Interior.

Noubar Afeyan, PhDNoubar Afeyan, PhD, Managing Partnerand CEONoubar Afeyan is Managing Partner andCEO of Flagship Ventures, a firm he co-founded in 2000. He is also a SeniorLecturer at MIT in both the Sloan Schoolof Management and the BiologicalEngineering Department. Dr. Afeyan hasauthored numerous scientific publica-

tions and patents since earning his Ph.D. in BiochemicalEngineering from MIT in 1987.A technologist, entrepreneur and venture capitalist, Dr.Afeyan has co-founded and helped build over 20 successfullife science and technology startups during the past twodecades. He was founder and CEO of PerSeptive Biosystems(Nasdaq: PBIO), a leader in the bio-instrumentation field.After PerSeptive’s acquisition by Applera Corporation(NYSE: ABI), he was Senior Vice President and ChiefBusiness Officer of Applera, where he initiated and oversawthe creation of Celera Genomics (Nasdaq: CRA).Currently Dr. Afeyan serves on a number of public and

private company boards. He is a director and co-founderof Flagship portfolio companies Affinnova, BG Medicine,Ensemble Discovery, Helicos BioSciences (NASDAQ:HLCS),

Joule Biotechnologies and LS9. Previously he was a mem-ber of the founding team, director and investor in severalsuccessful ventures including Chemgenics Pharmaceuticals,Color Kinetics, Antigenics, EXACT Sciences and AdnexusTherapeutics.Dr. Afeyan is a member of the Board of Overseers of

Boston University and the Board of Overseers of the BostonSymphony Orchestra. In addition, he is a member of sever-al advisory boards including the Whitehead Institute at MIT,the Harvard-MIT Division of Health Sciences and Technology(HST) and the SKOLKOVO School of Management inMoscow. Dr. Afeyan is also co-founder and board memberof Armenia 2020 and the National CompetitivenessFoundation of Armenia, two international economic devel-opment projects focusing on the former Soviet Republic ofArmenia. In 2008 he received an Ellis Island Medal ofHonor, an award granted to outstanding Americans whohave distinguished themselves as U.S. citizens and whohave enabled their ancestry groups to maintain their identi-ties while becoming integral parts of American life.

Samuel (Sandy) AronsonSandy Aronson is the Executive Directorof IT of the Partners Center forPersonalized Genetic Medicine (PCPGM)which was formally known as theHarvard Partners Center for Genetics andGenomics (HPCGG). In this position heoversees the development of IT infra-structure to support both the PCPGM’sgenetic and genomic core facilities and

the PCPGM’s clinically focused Laboratory for MolecularMedicine. This includes the development of portal, LIMSand repository systems. Mr. Aronson’s group has collaborat-ed with other Partners Information Systems groups to inte-grate these systems with the Partners Electronic HealthRecord (EHR) and is focused on extending support forgenetics aware clinical decision support based on theseintegrations.Prior to this position, Mr. Aronson was an IT consultant to

the biotechnology industry working for Tribiosys. Mr.Aronson also held several position with SapientCorporation, was a Strategic Consultant for MonitorCompany and founded LearningAction, a web-based train-ing company now part of Best Software. Mr. Aronson holdsa Masters in Organizational Behavior and a Bachelors inComputer Science from Stanford University. He also holds aMasters in Biology from Harvard Extension School.

Conference Speakers

11

continued

Mara G. AspinallMara is President and CEO of On-Q-ityInc., an innovative personalized medi-cine company based in Waltham,Massachusetts. On-Q-ity: Oncology +Quality + Clarity. On-Q-ity revolutionizescancer patient care by guiding individualtreatment choices through proactiveinterventions. On-Q-ity enables clarity inthe choice of patient of therapy and the

real –time monitoring of therapy efficacy of an individualpatients’ treatment, remission and potential relapsethrough the molecular characterization of circulating tumorcells in the blood.For the last seven years, Mara was President of Genzyme

Genetics, leading provider of testing in the oncology andreproductive markets. Under Mara’s leadership, GenzymeGenetics set the standard for quality in the industry, whileprofitably growing at an unprecedented pace. She trans-formed the business – expanding its scope and reach tobecome one of the nation’s largest diagnostic laboratories.Previously, Mara served as President of GenzymePharmaceuticals where she restructured the business fromgeneric drug manufacturing to value-added custom produc-tion.Mara has been on the Board of Predictive Biosciences

since its inception, serving as Chairman for the last year.Mara is also a Board member of Blue Cross Blue Shield ofMassachusetts.Mara has an appointment as Lecturer in Health Care

Policy at Harvard Medical School and will teach a seminaron business and medicine each year.She is an active member of the Federal Secretary of

Health and Human Services’ Advisory Commission onGenetics, Health and Society as well as Vice Chairman ofthe Personalized Medicine Coalition. Most recently, she co-authored, “Realizing the Promise of Personalized Medicine”in the Harvard Business Review. Bain & Company, an inter-national strategic consulting firm, was where Mara startedher business career. She earned her MBA from Harvard andher BA from Tufts University.

Linda AveyLinda Avey is the founder of BrainstormResearch Foundation, a not-for-profitorganization focused on the study of thegenetics of brain health, specifically tar-geted toward families with a history ofAlzheimer’s disease. By leveragingexisting technology platforms and socialnetworking tools, Brainstorm’s mission isto create a global network of individuals

and empower them with their genetic information com-bined with web-based mechanisms for longitudinal trackingof brain functions. This is also a personal mission for

Linda, whose father-in-law suffered with Alzheimer’s.In 2006, Linda founded 23andMe, the personal genetics

company. She and her co-founder, Anne Wojcicki, pio-neered many of the concepts that led to the creation of anew consumer industry and the development of a DNAresearch and media platform. The company won TIMEmagazine’s Invention of the Year in 2008 and receivedinternational attention through featured articles in Wired,New York Times, Fortune, and on Oprah, the TODAY showand the BBC (additional coverage is listed here,www.23andme.com/about/news/). While no longer actingin a day-to-day role, Linda supports the company’s efforts.Linda’s career spans over 20 years in the biopharmaceuti-

cal and academic research industry. Her experiences atAffymetrix, Perlegen Sciences, Spotfire, Chemdex, AppliedBiosystems and Molecular Dynamics provided an intensiveview into the mechanisms of the traditional researchmodel. With that insight came the idea of creating a new,complementary and consumer-based approach that thrivestoday at 23andMe and is the motivation for Brainstorm.Linda has a Bachelor of Arts in biology from Augustana

College.

Alison E. AyersAlison Ayers is responsible for globalstrategic and commercial leadership forPfizer’s oncology portfolio includingSutent, a leading anti-angiogenesisagent as well as 20+ agents in clinicaldevelopment and extensive lifecycleplanning. She is a member of theOncology Business Unit Leadership Teamwhich develops the Oncology TA

Strategic Plan, and manages the portfolio including assetprioritization, development planning, strategic and invest-ment decisions including licensing and acquisitions. She isresponsible for the global commercial strategy for Pfizer’soncology portfolio, which had sales of over $2billion in2008.Previously positions include Vice President of New

Product Marketing for Pharmacia Oncology, where she wasresponsible for providing commercial leadership forPharmacia’s oncology pipeline, and served a pivotal role inthe acquisition of Sugen, which delivered Pfizer’s leadingangiogenesis inhibitor, Sutent.Ayers has held senior positions in marketing, business

development and operations for several bioscience andpharmaceutical companies including Merck, BMS, USBioscience (Medimmune) and Lederle Laboratories (Wyeth).Ayers received a B.S. with honors in physiology and bio-

chemistry from the University of Southampton, UK. Shelater received a diploma in business studies from NorthLondon University, UK, and went on to earn a M.S. with dis-tinction in biopharmacy from London University, UK.

12

Conference Speakers continued

Troyen A. Brennan, M.D., M.P.H.Troyen A. Brennan, M.D., M.P.H., isExecutive Vice President and ChiefMedical Officer of CVS Caremark. Inthis role, Dr. Brennan directs CVSCaremark’s clinical affairs and overseesstrategy development. Prior to joiningCVS Caremark, Dr. Brennan was ChiefMedical Officer of Aetna Inc. From 2000to 2005, Dr. Brennan served as President

and CEO of Brigham and Women’s Physician’sOrganization. In his academic work, he was Professor ofMedicine at Harvard Medical School, and Professor of Lawand Public Health at Harvard School of Public Health. Dr.Brennan received his M.D. and M.P.H. degrees from YaleMedical School and his J.D. degree from Yale Law School.He completed his internship and residency in internal medi-cine at Massachusetts General Hospital. He is a member ofthe Institute of Medicine of the National Academy ofSciences.

G. Steven BurrillG. Steven Burrill has been involved inthe growth and prosperity of thebiotechnology industry for over 40 years.An early pioneer, Mr. Burrill is one of theoriginal architects of the industry andone of its most avid and sustaineddevelopers. He currently serves asChairman of the Boards of Pharmasset(NASDAQ: VRUS), BioImagene and

NewBridge, and is a member of the Boards of Directors ofCatalyst Biosciences, DepoMed (NASDAQ: DEPO), IkanoTherapeutics, Proteogenix, Proventys, Targacept (NASDAQ:TRGT) and XDx. Prior to founding Burrill & Company in1994, he spent 28 years with Ernst & Young, directing andcoordinating the firm's services to clients in the biotechnol-ogy/life sciences/high technology/manufacturing industriesworldwide. In 2002, Mr. Burrill was recognized as thebiotech investment visionary by the prestigious ScientificAmerican magazine (The Scientific American 50), and in2008, he received the BayBio Pantheon 2008 DiNA lifetimeachievement award for his worldwide biotech leadership.In addition to his work with leading life science compa-

nies, Mr. Burrill is a founder and currently serves as theChairman of the Board of the Foundation for the NationalMedals of Science and Technology. Additionally, he servesas Chairman of the San Francisco Mayor’s Biotech AdvisoryCommittee (MAYBAC). Other not-for-profit activities includeserving on the Boards of Directors of the Bay Area ScienceInfrastructure Consortium, BayBio, California HealthcareInstitute (Emeritus), The Exploratorium, The Kellogg Centerfor Biotechnology, the University of Maryland BiotechnologyInstitute, the MIT Center for Biomedical Innovation,Kramden Institute, and the National Health Museum. He

also serves on the Purdue Discovery Park External AdvisoryCommittee as well as the editorial board of the Journal ofCommercial Biotechnology, is on the advisory board of theCenter for Policy on Emerging Technologies (C-PET) andserves as an advisor to University of Illinois Institute forGenomic Biology, University of Wisconsin—College ofAgriculture and Life Sciences, and Duke University, and is anadjunct professor at University of California, San Francisco.

Brook ByersBrook Byers has been a venture capitalinvestor since 1972. He has been closelyinvolved with more than fifty new tech-nology based ventures, over half ofwhich have already become public com-panies. He formed the first Life Sciencespractice group in the venture capital pro-fession in 1984 and led KPCB to becomea premier venture capital firm in the

medical, healthcare, and biotechnology sectors. KPCB hasinvested in and helped build over 110 Life Sciences compa-nies which have already developed hundreds of products totreat major underserved medical needs for millions ofpatients.Brook was the founding President and then Chairman, of

four biotechnology companies which were incubated inKPCB’s offices and went on to become public companieswith an aggregate market value over $8 Billion. He is cur-rently on the Board of Directors of ten companies, mostrecently joining CardioDX, Genomic Health Incorporated,Five Prime Therapeutics, OptiMedica, Pacific Biosciences,Inc., Tethys and XDx, Inc. He was formerly a Director of IdecPharmaceuticals (Chairman), Athena Neurosciences(Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals,Pharmacopeia, Onyx Pharmaceuticals, Hybritech(Chairman), Genprobe and others. These companies havepioneered the medical use of molecular biology, monoclon-al antibodies, personalized medicine, molecular diagnosticsand genomics.Brook was President and a Director of the Western

Association of Venture Capitalists. He is a currently a Boardmember of the University of California at San FranciscoMedical Foundation, the New Schools Foundation,Stanford’s Bio-X Advisory Council and the Stanford EyeCouncil. He was Co-Chair of the five year, $1.4 billion, UCSFCapital Campaign. In 2007, he was awarded the “UCSFMedal” as their honorary degree equivalent. In 2008, hewas elected a Fellow of the American Academy of Arts andSciences. In 2009, he received the Lifetime AchievementAward from the National Venture Capital Association.He was formerly a Director of the Entrepreneurs

Foundation, the California Healthcare Institute, the AsianArt Museum in San Francisco, the Stanford Graduate Schoolof Business Advisory Council, That Many May See (UCSF)Vision Research Foundation (Chairman), the Georgia Tech

13

Advisory Board and was a founder of TechNet.Raised in Atlanta, Georgia, Brook graduated in Electrical

Engineering from Georgia Tech and received an MBA fromStanford.

Pierre CassigneulPierre Cassigneul is the CEO of XDxsince 2003. Prior to this he was a part-ner with the consulting firm, StoneBridge. Formerly he was at BectonDickinson. As Vice President DiabetesManagement, he led the company’sefforts in entering the blood glucosemonitoring market. Pierre also workedat Bayer where he was Senior VP and

General Manager of the Diabetes business unit, at Ortho(J&J) where he was VP and GM of the AIDS and HepatitisBusiness Unit, and at Abbott where he held several US andEuropean general management and marketing positions.Pierre has a management degree from the ESC Reims.

Brett DavisBrett Davis is a Senior Director inOracle's Health Sciences Global BusinessUnit. In this role, Brett is responsible forshaping and driving Oracle's personal-ized healthcare strategy and solutions.He works closely with leaders in health-care and life sciences to help themleverage innovative information tech-nologies and applications to innovate

and grow.In addition to his role at Oracle, he is on the Board of

Directors of the Personalized Medicine Coalition, is onHRSA’s Genetic Services Policy Project Advisory Panel, is aStrategic Advisor for the Ben and Catherine Ivy Foundationfor glioma research, and has been an invited speaker atindustry meetings on information technology’s transforma-tive role in the health sciences.Prior to joining Oracle, Brett was a Business Unit

Executive in IBM's Healthcare and Life Sciences business.In this role, he was involved in helping shape IBM’s strategyfor health analytics, clinical genomics, high performance sci-entific computing, biobanking and translational medicine.Prior to joining IBM, Brett led business development andmarketing efforts at Genstruct, Inc., a Cambridge, MAbased biotech. Previously he served as Senior ProductManager and Director of Marketing for Viaken Systems,Inc., where he helped develop and market bioinformaticsand knowledge management solutions for pharmaceuticalresearch.Brett is a graduate of The Pennsylvania State University

where he was enrolled in the accelerated Science BS/MBAProgram, and graduated as the Eberly College of ScienceStudent Marshall.

Susan DentzerSusan Dentzer is the Editor-in-Chief ofHealth Affairs, the nation’s leading jour-nal of health policy, and an on-air ana-lyst on health issues with The NewsHourwith Jim Lehrer on the PublicBroadcasting Service (PBS). Dentzerassumed the job of Editor-in-Chief onMay 1, 2008, after a decade as the on-air health correspondent for The

NewsHour.Prior to joining The NewsHour in 1998, Dentzer was chief

economics correspondent and economics columnist for U.S.News & World Report, where she served from 1987 to1997. Before joining U.S. News, Dentzer was at Newsweek,where she was a senior writer covering business news until1987. Dentzer’s work in television has included appear-ances as a regular analyst or commentator on CNN and TheMcLaughlin Group.Among the many organizations with which she is

involved, she is Chair of the Board of Directors of theGlobal Health Council, she is on the Board of Directors ofthe International Rescue Committee and heads it’s HealthCommittee which oversees the organization’s health pro-grams in 25 countries, she is a member of the KaiserCommission on Medicaid and the Uninsured, and she is amember of the National Advisory Committee of the RobertWood Johnson Foundation’s Investigator Awards in HealthPolicy Research.An alumna of Dartmouth College, Dentzer previously

served on its Board of Trustees and was the Board’s firstfemale chair. She is a member of the Board of Overseers ofDartmouth Medical School and a former trustee ofDartmouth-Hitchcock Medical Center.In 2009 Dentzer was elected to membership in the

Institute of Medicine of the National Academy of Sciences.

Richard DingRichard Ding has over 15 years ofresearch and management experience inthe pharmaceutical and diagnosticsindustry. As a member of the team atMyriad Genetics that cloned BRCA1gene, he made significant contribution tothe development of one of the firstmolecular genetic tests. Prior to joiningbioMerieux, he took various cross-func-

tional positions at Eli Lilly and company. In addition to hiscurrent role at bioMerieux as VP for Strategy and BusinessDevelopment, Richard Ding serves as the CEO ofbioTheranostics, a wholly-owned subsidiary of bioMerieux.Richard Ding holds an MBA from the University of Utah andreceived his undergraduate education at Fudan University,China.

continued

14

Conference Speakers continued

Frank L. Douglas, PhD, MDFrank L. Douglas, PhD, MD, is a seniorfellow at the Ewing Marion KauffmanFoundation, president and CEO ofAusten BioInnovation Institute (Akron,Ohio), senior partner of PureTechVentures (Boston, MA), and the founderand first executive director of the MITCenter for Biomedical Innovation. AtMIT, he was the Professor of the Practice

in the MIT Sloan School of Management and also heldappointments in the departments of biology, biologicalengineering, and the Harvard-MIT Division of HealthSciences and Technology.Dr. Douglas was formerly executive vice president, chief

scientific officer, and a member of the board of manage-ment of Aventis, where he headed drug innovation andapproval, with global responsibilities for research, develop-ment, and regulatory and marketing support. A leader ininnovation in pharmaceutical research and development, Dr.Douglas serves on multiple boards of directors, most recent-ly joining that of the Multiple Myeloma ResearchFoundation.Dr. Douglas is the recipient of the 2007 Black HistoryMakers Award and has been honored twice as the GlobalPharmaceutical R&D Director of the Year. He has alsoreceived the Medal of Honor and an Honorary Professorshipfrom the Johann Wolfgang von Goethe University, Frankfurt,Germany.Dr. Douglas holds a PhD in physical chemistry and a MD

from Cornell University. He did his internship and residencyin internal medicine at the Johns Hopkins MedicalInstitution and a fellowship in neuroendocrinology at theNational Institutes of Health

Robert S. Epstein, MDDr. Robert S. Epstein joined Medco in1995 and has served as Medco’s SeniorVice President of Medical & AnalyticalAffairs and Chief Medical Officer since1997. In this capacity, he is responsiblefor formulary development, clinicalguidelines, drug information services,accreditation oversight, and personal-ized medicine services. He is also

responsible for analysis and reporting for Medco’s clients.Dr. Epstein was trained as an epidemiologist, and worked inpublic health and academia before joining the private sec-tor. He is past elected President of the International Societyof Pharmacoeconomics and Outcomes Research, and hasserved on the Board of Directors for the Drug InformationAssociation. In 2008, Dr. Epstein was nominated and elect-ed on to the Federal CDC EGAPP (Evaluation of GenomicApplications in Practice & Prevention) StakeholderCommittee, and the AHRQ CERT (Centers for Education andResearch on Therapeutics) Committee. He has published

more than 50 peer reviewed medical articles and bookchapters, and serves as a reviewer for several influentialmedical journals.

Lori M. Evans, M.P.H., MMPLori M. Evans, M.P.H., MMP, DeputyCommissioner, Office of HealthInformation Technology Transformation,New York State Department of HealthLori M. Evans is the Deputy

Commissioner for the new Office ofHealth Information TechnologyTransformation, where she is responsiblefor leading State and private-sector

efforts to improve health care quality, accountability andefficiency through widespread deployment of health infor-mation technology.Ms. Evans served as a senior adviser to Dr. David Brailer,

the nation’s first national coordinator for health informationtechnology in the U.S. Department of Health and HumanServices, and was responsible for launching landmark initia-tives for the certification of health information tools, mod-ernization of health information standards, nationwideinformation-sharing architectures, and evaluation of newpolicies for protecting consumer privacy. Most recently, sheserved as a Managing Director of Manatt Health Solutions,a national health care policy and business advisory divisionof Manatt, Phelps and Phillips, leading the health informa-tion technology practice. Additionally, she has held manage-ment positions at the eHealth Initiative and CareScienceInc. She has served as a senior consultant with thePermanente Medical Group, as well as a policy analyst andresearch scientist at the University of California SanFrancisco and the George Washington University.

John A. Fallon, MD, MBA, FACPJohn is responsible for ensuring thehighest standards of medical care forour members. He is also accountable forhelping expand health care strategiesinvolving quality, effectiveness, efficiencyand their relationships to new paymentmethodologies. He oversees the compa-ny’s medical policies, acts as the mainliaison with the plan’s provider network,

reviews upcoming legislation for medical impact, managesthe company’s medical directors, acts as primary spokesper-son for medical inquires and main medical contact with theBlue Cross Blue Shield Association and its 39 plans.John practiced Internal Medicine for over 20 years.

Additionally, he was previously CEO for the entire clinicalenterprise at the State University of New York’s DownstateMedical Center. His professional experience also includesthe Partners Healthcare System, where he was Chairman ofthe physician network. He was also the founder and CEOof North Shore Health System, a large physician-hospital

15

organization in Massachusetts.He serves on many boards; locally, among them are the

Neighborhood Health Plan and the New EnglandHealthcare Institute, nationally the NCQA MedicalStandards, and Temple University School of Medicine Boardof Advisors. Currently is co-chair of the State ofMassachusetts Patient Centered Medical Home InitiativeCoordination Council.John is Board Certified in Internal Medicine, a Clinical

Professor in the Graduate Program of Public Health atSUNY Downstate Medical Center College of Medicine andis a Fellow of the American College of Physicians.

Jon FriedenbergJon Friedenberg became a Vice Presidentof El Camino Hospital in 2002. He hasalso played a leadership role in the cre-ation of the South Asian Heart Center,The Fogarty Institute for Innovation andthe Genomic Medicine Institute. Jonreceived his Bachelor of Arts from theUniversity of California, Berkeley and aMaster of Arts from the University of

California, Davis. Jon was also a Fellow with the CaliforniaHealthcare Leadership College and the Wexner HeritageFoundation.

John Glaser, PhDJohn Glaser, PhD, is Vice-President andChief Information Officer, PartnersHealthCare System, Inc. Previously, hewas Vice-President, Information Systemsat Brigham and Women’s Hospital. Priorto Brigham and Women's Hospital, Dr.Glaser managed the HealthcareInformation Systems consulting practiceat Arthur D. Little.

Dr. Glaser was the founding Chairman of College ofHealthcare Information Management Executives (CHIME)and is past President of the Healthcare Information andManagement Systems Society (HIMSS). He is past-Presidentof the eHealth Initiative and has been a member of theBoard of the American Medical Informatics Association.Dr. Glaser is a former member of the Board of the

National eHealth Collaborative. He is the former co-Chair ofthe Board of the National Alliance for HealthcareInformation Technology. He has been a Senior Advisor tothe Deloitte Center for Health Solutions.Dr. Glaser is a Senior Advisor, Office of the National

Coordinator for Health Information Technology, HHS.He is a fellow of HIMSS, CHIME and the American

College of Medical Informatics. He has been awarded theJohn Gall award for healthcare CIO of the year. CHIME hasestablished a scholarship in Dr. Glaser’s name. He waselected to CIO Magazine’s CIO Hall of Fame. Partners

HealthCare has received several industry awards for itseffective and innovative use of information technology.Dr. Glaser has published over one hundred and fifty arti-

cles and three books on the strategic application of infor-mation technology in healthcare.He holds a Ph.D. in Healthcare Information Systems from

the University of Minnesota.

Gary L. Gottlieb, M.D., M.B.A.Gary L. Gottlieb, M.D., M.B.A., serves asPresident of Brigham andWomen’s/Faulkner Hospitals; a positionhe has held since March 1, 2002. He is aProfessor of Psychiatry at the HarvardMedical School.Partners HealthCare recruited Dr.

Gottlieb to become the first chairman ofPartners Psychiatry in 1998 and he

served in that capacity through 2005. In 2000, he addedthe role of President of the North Shore Medical Centerwhere he served until early 2002.Prior to coming to Boston, Dr. Gottlieb spent 15 years in

positions of increasing leadership in health care inPhiladelphia. In 1983, he arrived at the University ofPennsylvania as a Robert Wood Johnson Foundation ClinicalScholar. Through that program, he earned an M.B.A withDistinction in Health Care Administration from Penn’sWharton Graduate School of Business Administration. Hecredits the program with building a foundation of interestin health policy, management and academic leadership.Dr. Gottlieb went on to establish Penn Medical Center’s

first program in geriatric psychiatry and developed it into anationally recognized research, training and clinical pro-gram. Dr. Gottlieb rose to become Executive Vice Chair andInterim Chair of Penn’s Department of Psychiatry and theHealth System’s Associate Dean for Managed Care. In 1994,he became Director and Chief Executive Officer of FriendsHospital in Philadelphia, the nation’s oldest, independent,freestanding psychiatric hospital.In addition to his noteworthy academic, clinical and man-

agement record, Dr. Gottlieb has published extensively ingeriatric psychiatry and health care policy. He is a pastPresident of the American Association of GeriatricPsychiatry. Dr. Gottlieb received his BS cum laude from theRensselaer Polytechnic Institute and his M.D. from theAlbany Medical College of Union University in a six-yearaccelerated biomedical program. He completed his intern-ship and residency and served as Chief Resident at NewYork University/Bellevue Medical Center.Now, as a recognized community leader in Boston, Dr.

Gottlieb also focuses his attention on workforce develop-ment and disparities in health care. He was appointed byMayor Thomas Menino as Chairman of the Private IndustryCouncil, the City’s workforce development board, whichpartners with education, labor, higher education, the com-

continued

16

Conference Speakers continued

munity and government, to provide oversight and leader-ship to public and private workforce development pro-grams. In 2004-2005, he served as co-chair of the Mayor’sTask Force to Eliminate Health Disparities.Dr. Gottlieb is slated to become the President and CEO of

Partners HealthCare System in January, 2010.Brigham and Women’s Hospital (BWH) is a 777-bed non-

profit teaching affiliate of Harvard Medical School and afounding member of Partners HealthCare, an integratedhealth care delivery network. BWH is committed to excel-lence in patient care with expertise in virtually every spe-cialty of medicine and surgery. The BWH medical preemi-nence dates back to 1832, and today that rich history inclinical care is coupled with its national leadership in quali-ty improvement and patient safety initiatives and its dedi-cation to educating and training the next generation ofhealth care professionals. In July of 2008, the hospitalopened the Carl J. and Ruth Shapiro Cardiovascular Center,the most advanced center of its kind. Through investigationand discovery conducted at its Biomedical ResearchInstitute (BRI), BWH is an international leader in basic, clini-cal and translational research on human diseases, involvingmore than 860 physician-investigators and renowned bio-medical scientists and faculty supported by more than $416M in funding. BWH is also home to major landmark epi-demiologic population studies, including the Nurses’ andPhysicians’ Health Studies and the Women’s HealthInitiative.

Daniel A. Haber, MD, PhDDr. Haber was born in Paris, France, andreceived both his MD and PhD atStanford University School of Medicinein 1983. He completed his internshipand residency in internal medicine atMassachusetts General Hospital, fol-lowed by clinical oncology training atDana-Farber Cancer Institute and post-doctoral research at MIT. Dr. Haber has

led a research team at MGH since 1991, with specific inter-ests in the genetics of Wilms tumor and breast cancer. Hewas promoted to Professor of Medicine at Harvard MedicalSchool in 2001 and appointed Director of theMassachusetts General Hospital Cancer Center in 2003. In2008, he was appointed Investigator of the Howard HughesMedical Institute.Dr. Haber was elected to the American Society for Clinical

Investigation (ASCI) in 1995 and the American Associationof Physicians (AAP) in 2003. He is recognized for his scien-tific accomplishments in the genetics of cancer and herecently led the MGH team that discovered the linkbetween mutations in the epidermal growth factor receptorgene and response of lung cancer to the new “targeted”drug gefitinib (Iressa). His laboratory has recently reportedthe application of genetic analysis of circulating tumor cells

in blood samples from patients with lung cancer, using anovel microfluidic technology. Dr. Haber received a “DreamTeam Award” from the Stand Up To Cancer telethon tosupport development and application of this technology.

Richard G. HamermeshMBA Class of 1961 Professor ofManagement PracticeRichard Hamermesh is the MBA Class of1961 Professor of Management Practiceat the Harvard Business School wherehe teaches in the MBA Program and isthe Faculty Chair of the HBS HealthcareInitiative. Richard created and teachesthe second-year MBA elective,

Entrepreneurship and Venture Capital in Healthcare.Previously, he was the Course Head for the required firstyear course entitled The Entrepreneurial Manager. In addi-tion Richard participates in several HBS Executive Educationprograms.From 1987 to 2001, Richard was a co-founder and aManaging Partner of The Center for Executive Development,an executive education and development consulting firm.Prior to this, from 1976 to 1987, he was a member of thefaculty of the Harvard Business School.Richard is also an active investor and entrepreneur, hav-

ing participated as a principal, director, and investor in thefounding and early stages of over 20 organizations. Thesehave included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding presi-dent of the Newton (MA) Schools Foundation and servedon the editorial board of the Harvard Business Review. He iscurrently on the Boards of one public and two private cor-porations, as well as two non-profit Boards. From 1991 to1996, he was the founding Chairman of Synthes Spine, Inc.Richard is the author or co-author of five books, includingNew Business Ventures and the Entrepreneur. His best-known book, Fad-Free Management, was published in1996. He has published numerous articles and more than100 case studies. His most recent article, "Realizing thePotential of Personalized Medicine," appeared in theHarvard Business Review (October 2007). Richard receivedhis AB from the University of California, and his MBA andDBA from HBS. He is married, has two children, and hishobbies include tennis, skiing, and yoga.

Arlene R. Hughes, PhD.Arlene R. Hughes, Ph.D. earned herBachelor of Arts degrees in chemistryand biology at the University ofDelaware. She then obtained her PhD inPharmacology from the University ofNorth Carolina at Chapel Hill and com-pleted post-doctoral training in molecu-lar pharmacology at the National

17

Institute of Environmental Health Sciences.Dr. Hughes joined the pharmaceutical industry as a clini-

cal research scientist and has held positions of increasingresponsibility in the Neurosciences Clinical Developmentgroup at GlaxoSmithKline’s legacy companies, BurroughsWellcome and GlaxoWellcome. Twelve years ago, Arlenejoined GlaxoSmithKline’s Genetics group where she hasworked with drug development teams to identify pharma-cogenetic opportunities for a number of projects. She wasintegrally involved in GlaxoSmithKline’s efforts to identifygenetic risk factors for hypersensitivity to abacavir, a treat-ment limiting and potentially life threatening adverseevent. This project successfully identified a genetic marker,HLA-B*5701, associated with risk of abacavir hypersensitiv-ity and demonstrated its clinical utility. Implementation ofprospective screening and exclusion of HLA-B*5701 posi-tive patients from abacavir therapy has significantlyreduced the incidence of abacavir hypersensitivity. In 2008,Arlene was appointed Genetics Therapy Area Head forInfectious Diseases where she supports GSK’s portfolio ofantibacterial, antiviral and diseases of the developing worldcompounds and marketed medicines.

Dr. Gerardo Jimenez-SanchezDr. Gerardo Jimenez-Sanchez was bornin Mexico City. He obtained his MedicalDoctor degree from the NationalAutonomous University of Mexico(UNAM). He did his residency inPediatrics at the National Institute ofPediatrics and earned his Ph.D. Degreein Human Genetics and MolecularBiology from the Johns Hopkins

University in Baltimore, MD, USA.Dr. Jimenez-Sanchez is Professor of Genomic at the

UNAM and Resident Investigator of the Mexican HealthFoundation (FUNSALUD). He is also Director General of theNational Institute of Genomic Medicine and affiliate mem-ber of the Institute of Genetic Medicine at Johns HopkinsUniversity. His actual work focuses on the development of anational platform in genomic medicine for Mexico. Thisincludes the conduction of major scientific research proj-ects, including the production of the first haplotype map forthe Mexican Mestizo population.Dr. Jimenez-Sanchez is a certified pediatrician and a

member of the Mexican Academy of Pediatrics, the NationalAcademy of Medicine, the Mexican Society of Biochemistryand the American Societies of Human Genetics, InbornErrors of Metabolism and Gene Therapy, the EuropeanSociety of Inborn Errors of Metabolism and the HumanGenome Organization (HUGO).Dr. Jimenez-Sanchez work has resulted in the publication

of articles and chapters in specialized journals and books.He received the Research in Pediatrics Award of the Societyfor Pediatric Research in 1999. Along with his colleaguesDavid Valle and Barton Childs, he did the first medical

analysis of the human genome, published with the firstdraft of the human genome in 2001. He received theNational Award in Clinical Investigation “Dr. Miguel Otero”from the Government of Mexico. In April of 2003, he wasappointed Silanes Professor in Genomic Medicine. He is theregional editor for Latin America and the Carribean of theJournal Genomic Medicine and charter member of the inter-national Public Population Project in Genomics (P3GConsortium).

David P. KingDavid P. King is Chairman and ChiefExecutive Officer of LaboratoryCorporation of America® Holdings(LabCorp). LabCorp, one of the world’slargest clinical laboratories, has rev-enues of approximately $4.5 billion(2008) and more than 28,000 employ-ees nationwide.Prior to becoming Chief Executive

Officer on January 1, 2007, Mr. King served as LabCorp’sExecutive Vice President and Chief Operating Officer since2005. Previously, he served as head of the Company’s USLABS / Esoterix Division, one of the nation’s leading special-ty testing and cancer diagnostic laboratories, as well asExecutive Vice President of Strategic Planning andCorporate Development. He is a member of the Company’sManagement Committee.Mr. King initially joined LabCorp as Senior Vice President,

General Counsel and Chief Compliance Officer in 2001 afterworking for many years with the Company as an outsidecounsel. Prior to joining the Company, he was a partnerwith Hogan & Hartson L.L.P. in Baltimore, Maryland from1992 to 2001.Mr. King is also on the board of The Personalized

Medicine Coalition (PMC) which seeks to advance theunderstanding and adoption of personalized medicine con-cepts and products for the benefit of patients.Mr. King, 53, holds an AB degree, cum laude, from

Princeton University and a JD degree, cum laude, from theUniversity of Pennsylvania Law School.

Raju Kucherlapati, Ph.D.Raju Kucherlapati came to the UnitedStates in 1967 after receiving his B.S. inBiology at P.R. College, Kakinada, Indiaand his M.S. in Biology at AndhraUniversity, Waltair, India. He receivedhis Ph.D. from the University of Illinoisat Urbana and did his post-doctoralwork in the lab of Frank Ruddle at YaleUniversity. He was assistant professor

in the Department of Biochemical Sciences at PrincetonUniversity, then became professor in the Department ofGenetics at the University of Illinois College of Medicine. In

continued

18

Conference Speakers continued

1989 Dr. Kucherlapati went to the Albert Einstein College ofMedicine where he was the Lola and Saul Kramer Professorof Molecular Genetics and Chairman of the Department ofMolecular Genetics, a position he held for eleven years. In2001 Dr. Kucherlapati became the Paul C. Cabot Professorof Genetics and Professor of Medicine at Harvard MedicalSchool and was the first Scientific Director of the HarvardMedical School-Partners HealthCare Center for Geneticsand Genomics (HPCGG).At HPCGG Dr. Kucherlapati devoted his energies to

advancing the cause of personalized medicine. Under hisdirection HPCGG launched initiatives that resulted in alarge number of novel molecular diagnostics; built newinformation technology programs that captured the resultsof clinical and basic genetic research in structured formatsthat could then be applied meaningfully in clinical decisionmaking that would benefit diagnosis, prognosis and treat-ment of patients. He also strengthened and developed newtraining and educational programs for physicians, scientists,healthcare professionals, patients, and others in humangenetics and genomics and the application of genetics inhealthcare. He stepped down as the Scientific Director ofthe Center in late 2008. He continues to promote personal-ized medicine in all of its facets at the national level.Dr. Kucherlapati contributed to several different areas of

research. These include gene targeting and homologousrecombination, human gene mapping, generation of physi-cal maps of the human genome with special emphasis onhuman chromosome 12, development of techniques tomodify genes in mammalian cells and in cloning manyhuman disease genes. To date he holds 12 patents. He wasa member and Chair of several review committees at theNIH, was a member of the National Advisory Council forHuman Genome Research at the National Human GenomicsResearch Institute, and was a co-chair of the steering com-mittee for the National Cancer Institute’s Mouse Models forHuman Cancer Consortium. He served on the editorialboard of the New England Journal of Medicine and waseditor in chief of the journal Genomics. He is a fellow ofthe American Association for the Advancement of Scienceand a member of the Institute of Medicine of the NationalAcademy of Sciences.Dr. Kucherlapati was a founder of Cell Genesys, Abgenix

and Millennium Pharmaceuticals. He currently serves onthe boards of privately held AVEO Pharmaceuticals andEnlight Biosciences.

Lawrence J. Lesko, Ph.D., F.C.P.Lawrence J. Lesko, Ph.D., F.C.P. is theDirector of the Office of ClinicalPharmacology (OCP) in the Center forDrug Evaluation and Research at theFood and Drug Administration (FDA)having served in this capacity since1995. The main services of OCP arepharmacogenomics and individualiza-

tion of therapies, the analysis of dose-response and PK-PDdata for the purpose of optimizing dose selection, the useof biomarkers to assist in benefit/risk assessments, makingdosing adjustments for drug-drug interactions and in spe-cial populations (e.g., renal patients), evaluating benefitand risk in patient subsets defined by genomic factors, andindividualizing drug therapy in product labels. The OCPalso utilizes quantitative methods and drug-disease state-trial models to prospectively evaluate options for designingrandomized clinical trials through simulation. Dr. Lesko isChair of the FDA Pharmacogenomics Working Group andthe Clinical Pharmacology Section of the Medical PolicyCoordinating Committee in CDER, both of which areresponsible for the development of guidances for industryand enabling of innovative technologies for drug develop-ment and re-labeling of approved medicines with geneticinformation. Dr. Lesko has served as the President of theAmerican College of Clinical Pharmacology (ACCP) from2004-2006. He has received the ASCPT Rawls-PalmerProgess in Medicine Award in March 2007, was honoredwith the University of North Carolina (UNC) Institute forPharmacogenomics and Individualized Therapy Award forClinical Service in May 2007, and was awarded theNathaniel T Kwit Memorial Distinguished Service Awardfrom ACCP in September 2007. He has been appointed asan Adjunct Professor in the Colleges of Pharmacy at theUniversity of Florida, at Univesity of North Carolina, OhioState University, and at the University of SouthernCalifornia. Dr. Lesko is an elected American Association ofPharmaceutical Scientist (AAPS) Fellow, a Fellow in theACCP and a Japanese Society for the Study of Xenobiotics(JSSX) Fellow. He is Board Certified in ClinicalPharmacology by the American Board of ClinicalPharmacology. He has authored over 160 peer-reviewedmanuscripts and is a frequent invited speaker nationallyand internationally. His hobbies include motocycles, scubadiving and underwater photography. He is a Divemastercertified by the Professional Association of DivingInstructors.

19

Mark LevinMark Levin co-founded Third RockVentures in May 2007 and focuses onthe formation, development and busi-ness strategy of their portfolio compa-nies as well as actively identifying andevaluating new investments. Mark hasmore than 25 years of experience build-ing and operating leading biotech com-panies. After 10 years at Lilly and

Genentech, Mark was co-Founder of Mayfield Fund’s lifesciences effort where he was founding CEO of Turalik, CellGenesys/Abgenix, Focal, Stem Cells and MillenniumPharmaceuticals. Mark was at Millennium as CEO for 12years. Mark is a co-Founder of Young Entrepreneurs inCambridge MA, a Member of the National Academy ofEngineering and Member of Friends of PersonalizedMedicine.Mark holds an M.S. in Chemical and Biomedical

Engineering from Washington University and is a BoardMember of Seventh Sense Pharmaceuticals, ConstellationPharmaceuticals, and DC Devices.

Sharon Levine, MDSharon Levine, MD, Associate ExecutiveDirector for The Permanente MedicalGroup of Northern California since 1991,has responsibility for clinical education,management training and leadershipdevelopment for the group’s physicians;government and community relations,health policy and external affairs; andpharmacy policy and drug use manage-

ment. A board certified pediatrician, Dr. Levine has heldmultiple leadership roles within the Medical Group, as wellas academic appointments at Tufts University School ofMedicine and Georgetown University School of Medicine,and spent two years as a Clinical Associate at the NationalInstitutes of Health, Institute of Child Health and HumanDevelopment. Dr. Levine serves on the Boards of Directorsof the Integrated Healthcare Association, the Public HealthInstitute of California, the California Association ofPhysician Groups (CAPG), The Reagan Udall Foundation, theMedical Board of California and the California HospitalAssociation, and is a member of the Committee onEvidence-Based Benefit Design of the National BusinessGroup on Health. A native of Boston, Dr. Levine receivedher undergraduate degree from Radcliffe College atHarvard University, and her MD degree from Tufts UniversitySchool of Medicine. Dr. Levine is married and lives in PaloAlto, California.

Nick LittlefieldNick Littlefield, Partner and Chair,Government Strategies Group, at FoleyHoag LLP, a full service law firm locatedin Boston, Massachusetts andWashington, DC, concentrates his prac-tice on subjects including, scientificinnovation, biomedical research anddevelopment, personalized medicine,and health care technology. He special-

izes in regulatory, administrative, legislative and policyissues for large and small companies, non-profit organiza-tions and trade associations. Nick and his colleagues in theFoley Hoag Life Sciences Group work with clients on regula-tory matters before federal and state agencies including,the Centers for Medicare & Medicaid Services (CMS) andthe Food and Drug Administration (FDA), as well as on leg-islative matters in the Congress.For nine years until 1998, Nick served as Staff Director

and Chief Counsel for the late Massachusetts SenatorEdward M. Kennedy on the United States Senate Health,Education, Labor and Pensions Committee. During Mr.Littlefield’s tenure with Senator Kennedy such legislativeinitiatives as, the Health Insurance Portability andAccountability Act (1996), the Children’s Health InsuranceProgram (“CHIP”) (1997), the National Institutes of HealthRevitalization Act (1993), the Food & Drug AdministrationModernization Act (1997), the Ryan White AIDS Care Act(1990), the Family and Medical Leave Act (1993), andAmerican with Disabilities Act (1990), were enactedthrough the Committee.Mr. Littlefield is a member of the board or advisory com-

mittee for a number of non-profit healthcare policy organi-zations, including the Blue Cross Blue Shield ofMassachusetts Foundation, New England HealthcareInstitute (Executive Committee and Chair, PolicyCommittee), Massachusetts General Hospital/PartnersHealthCare System Institute for Health Policy (member ofthe Board of Advisors), Massachusetts Biotech Council (co-chair, Legal and Government Affairs Committee), and theHeller School of Social Policy, Brandeis (Board of Overseers).Previously, Mr. Littlefield taught at Harvard Law School asthe Edward Johnson Lecturer on Law from 1978 to 1989,and served as chief counsel to the Massachusetts SpecialAnti-Corruption Commission from 1978 to 1980 and asAssistant U.S. Attorney for the Southern District of New Yorkfrom 1972-1976. He received his AB from Harvard Collegeand LLB from the University of Pennsylvania Law School.

continued

20

Philip MaPhilip Ma is a Director in the SiliconValley Office of McKinsey & Company,and the leader of its West Coast health-care practice. Philip has served healthcare clients in the U.S., Europe, andJapan. He has worked with leadingplayers in the pharmaceuticals, biotech-nology, and medical products sectors ona variety of strategic, organizational,

and operational issues. In addition, he has led or co-ledmany of the Firm’s knowledge and external reputationbuilding efforts in these areas.Prior to joining McKinsey, Philip worked as a research sci-

entist in the Department of Biology at the MassachusettsInstitute of Technology, where he was involved in studyingthe atomic structures of proteins involved in gene regula-tion, using X-ray crystallography.Philip holds a Ph.D. in biology from the Massachusetts

Institute of Technology, an M.Phil. degree in economicsfrom Oxford University, where he was a Rhodes Scholar,and an A.B. degree from Harvard University

Douglas J. Moeller MDDouglas J. Moeller, M.D., has been aMedical Director with McKesson HealthSolutions since September 2003. His pri-mary accountability involves the clinicalintegrity of KnowledgeBase develop-ment for McKesson claims auditing andadvanced diagnostics management solu-tions. In addition, Dr. Moeller has majorresponsibilities in customer support, spe-

cial projects, and new product development. He also hasactive relationships with multiple professional medicalassociations with a focus on clinical coding and claims pro-cessing. He has shared this subject matter expertise inthese areas in published articles in national trade publica-tions and appeared in a variety of conference forums.Dr Moeller is a Board-certified General Internist and was

in private medical practice for 13 years before his transitioninto managed care and medical informatics.

Lee N. Newcomer, MD, MHALee N. Newcomer, MD, MHA, is theSenior Vice President, Oncology forUnitedHealthcare. His unit is responsi-ble for improving the quality and afford-ability of care for the 111,000 cancerpatients covered by United Healthcare.Prior to rejoining United Health Group

(UHG), Dr. Newcomer was a foundingexecutive of Vivius, a consumer directed

venture that allowed consumers to create their own per-sonalized health plans. From 1991 to 2000, Dr. Newcomer

held a number of positions at UHG, including Chief MedicalOfficer. His work there emphasized the development of per-formance measures and incentives to improve clinical care.Prior to joining UHG, he was Medical Director for CIGNAHealth Care of Kansas City.Dr. Newcomer is a board certified medical oncologist; he

practiced medical oncology for nine years in Tulsa,Oklahoma and Minneapolis (Park Nicollet Clinic).He is currently the Chairman of Park Nicollet Health

Services, an integrated system of over 650 physicians and a400 bed hospital. The group is nationally recognized for itsleadership in quality, safety and lean processes.Dr. Newcomer earned a Bachelor of Arts degree in biolo-

gy from Nebraska Wesleyan University, an MD degree fromthe University of Nebraska College of Medicine, and an MSdegree in health administration from the University ofWisconsin at Madison. He completed his internship and res-idency in internal medicine from the University of NebraskaHospital, and fellowships in medical oncology and adminis-trative medicine from the Yale University School ofMedicine and the University of Wisconsin at Madison,respectively.

Sir Michael RawlinsSir Michael Rawlins has been chairmanof the National Institute of Health &Clinical Excellence (NICE) since its for-mation in 1999. He is an HonoraryProfessor at the London School ofHygiene and Tropical Medicine,University of London, and EmeritusProfessor at the University of Newcastleupon Tyne. He was the Ruth and Lionel

Jacobson Professor of Clinical Pharmacology at theUniversity of Newcastle upon Tyne from 1973 to 2006 . Atthe same time he held the position of consultant physicianand consultant clinical pharmacologist to the NewcastleHospitals NHS Trust. He was vice-chairman (1987-1992) andchairman (1993-1998) of the Committee on Safety ofMedicines; and chairman of the Advisory Council on theMisuse of Drugs (1998-2008).

Marc S. Sabatine, MD, MPHMarc S. Sabatine, MD, MPH is anInvestigator in the Thrombolysis inMyocardial Infarction (TIMI) StudyGroup, an Associate Physician inCardiovascular Medicine at Brigham andWomen’s Hospital, and an AssistantProfessor of Medicine at HarvardMedical School.Dr. Sabatine graduated magna cum

laude in Biochemical Sciences from Harvard College andreceived his medical degree magna cum laude fromHarvard Medical School. He did his Internal Medicine resi-

Conference Speakers continued

21

dency and Cardiology clinical fellowship at the MassachusettsGeneral Hospital and his research fellowship at TIMI. Hereceived a Master of Public Health degree from the HarvardSchool of Public Health.Dr. Sabatine is an NIH R01-funded investigator whose

research focuses on optimizing the treatment of patients withacute coronary syndromes through (1) clinical trials of novelpharmacotherapies, (2) application of proteomics andmetabolomics for discovery of biomarkers for risk stratifica-tion, and (3) tailoring of therapy using pharmacogenetics. Dr.Sabatine has published extensively in these fields and hasauthored ~100 original research articles. He has been award-ed the American College of Cardiology Zipes DistinguishedYoung Scientist Award.

Vance Vanier, M.D.Dr. Vance Vanier is the Chief MedicalOfficer of Navigenics and a clinical facultymember of Stanford University MedicalCenter. As a former partner at venturecapital firm, Mohr Davidow Ventures, hehas spent years in the molecular diagnos-tics industry bringing new genomic tech-nologies into clinical practice. Dr. Vanierreceived his medical degree from the

Johns Hopkins School of Medicine and did his residency train-ing at the University of California, San Francisco, and HighlandHospital in Oakland, Calif. He serves as a member of thePersonalized Medicine Coalition’s Clinical Science Committee,Stanford Hospital’s Pharmacy and Therapeutics Committee,and the American College of Preventive Medicine. During hismedical career, he has had a strong commitment to interna-tional medicine — including traveling to Kosovo after the warto work with theWorld Health Organization in creating thenation’s first ambulance system. He received an MBA fromStanford University, as well as dual bachelor’s degrees withhonors.

Sheila D.WalcoffSheila D.Walcoff is a partner in the law firm of McDermottWill & Emery LLP, based in the Firm’s Washington, DC office.Sheila is a member of the Health Law Department and theFirm’s Life Sciences Government Strategies Practice Group. In2008, Sheila was appointed to the U.S. Department of Healthand Human Services (HHS) Secretary’s Advisory Committee onGenetics, Health, and Society (SACGHS). A recognized healthpolicy expert, Sheila focuses her practice on personalizedmedicine and other federal regulatory and science policy mat-ters. She counsels a broad range of clients, including pharma-ceutical and biotechnology companies, specialized laborato-ries, science and technology start-ups, and associations/ coali-tions on policy, government affairs advocacy, business strate-gy, and communications.Sheila has significant federal health policy, communications,

legislative/regulatory, and management experience. Sheserved as Counselor to the Secretary of the U.S. Department

of Health and Human Service (HHS) As Counselor, Sheilaadvised the HHS Secretary, theWhite House, and other gov-ernment agencies on all science and public health policy,management, communications and budget matters, includingpersonalized medicine. She developed and directed major HHSand Administration initiatives, including personalized healthcare, genomics and information technology, prevention,WorldTrade Center responder health care and HIV/AIDS initiatives.Sheila earned her J.D. in 1993 from the Georgetown

University Law Center and is affiliated with The FederalistSociety for Law & Policy, the American Health LawyersAssociation, the American Bar Association, and the AmericanVeterinary Medical Law Association.

Scott T.Weiss, M.D., M.S.Scott T.Weiss, M.D., M.S. is the InterimDirector of Partners HealthCare Center forPersonalized Genetic Medicine. He servesas Director of the Center for GenomicMedicine (Department of Medicine,Brigham &Women’s Hospital) andAssociate Director, Channing Laboratory,and Professor of Medicine at HarvardMedical School. In this capacity, he leads

a 25 investigator, 110 person research group examining theenvironmental and genetic origins of asthma and COPD.He has authored or coauthored over 500 publications and

four books in the area of asthma and COPD risk factors, natu-ral history, and genetics. His initial work concerned the role ofairways responsiveness and environmental tobacco smokeexposure in asthma and COPD, the effect of allergen exposureand airways responsiveness on markers of inflammation andthe combined effect of these factors on the development ofCOPD. In 1996, he developed a strong interest in the geneticsof asthma and his recent work has focused on this, and novelenvironmental exposures such as vitamin D and the bowelflora. His laboratory is the only laboratory in the world thathas active NIH research in the areas of asthma genetics, asth-ma pharmacogenetics, and COPD genetics. He is the principalinvestigator or co-investigator on a total of six separateNHLBI-funded grant proposals in the area of the genetics ofasthma and Asthma Pharmacogenetics, including a MERITaward.Dr.Weiss has international research experience in China,

The United Kingdom, Norway, Mexico, Costa Rica, and theNetherlands. Dr.Weiss is Principal Investigator of a longstanding T-32 Training grant (HL-07427). Dr Weiss has had 27trainees in the last 15 years, 25 of whom are still in academicmedicine. He has served in an administrative capacity withthe NHLBI including the Special Emphasis Panel on the Use ofNHLBI Specimens, the Oversight Committee for theCollaborative Study on the Genetics of Asthma, the NHLBIGenotyping Service Study Section, the T-32 review study sec-tion, and the oversight committee for the NHLBI re-sequenc-ing and genotyping facility.

22

The vision to dream big. At Siemens, we are devoted to bringing you the science you need to dream big—redefine early detection, develop innovative treatments, deliver truly personalized care. We are dedicated to improving the health and well-being of patients. And we’re committed to helping you every step of the way. Siemens is proud to sponsor the 2010 Personalized Medicine Conference. www.usa.siemens.com/healthcare 1-888-826-9702

Answers for life.

A 23-1026-A1-4A00 Corporate Office: 51 Valley Stream Parkway, Malvern, PA 19355-1406 USA +1-888-826-9702© 2009 Siemens Medical Solutions USA, Inc. All rights reserved.

It’s really that simple. And let’s face it, in

the (necessarily) complex world of health

and life sciences, a little simplicity can be

pretty refreshing. That’s why, at HP, we’re

developing technology to simplify the entire

ecosystem and help it run as efficiently and

remarkably as the human body itself.

Because our technology can do things like

speed up the process from R&D to real life,

it ultimately improves the quality of care,

and leads directly to better health

outcomes. Healthier, happier patients –

that’s what it’s all about.

The healthier the system,the healthier the patients.

ALTERNATIVE THINKING ABOUT HEALTH AND LIFE SCIENCES:

23

One focus: a shared commitment to improve the lives of cancer patients everywhere.

Now the innovative science of a leading American biopharmaceutical company joins the global assets of Takeda, Japan’s largest pharmaceutical company, for a global commitment to oncology.

Millennium: The Takeda Oncology Company is developing an extensive pipeline — among the top in oncology worldwide — with more than 13 compounds in development for a broad range of solid and hematological cancers.

Our pipeline — rich in novel compounds — includes multiple candidates that target six disease pathways: protein homeostasis, anti-angiogenesis, growth-signaling inhibition, cell-cycle inhibition, apoptosis and hormone regulation.

We are dedicated to a strong partnership with the oncology community. Together we can make a dramatic impact on cancer therapeutics over the next decade.

24

www.endo.com 1.800.462.ENDO© 2009 Endo Pharmaceuticals. All Rights Reserved

Endo is proud to sponsor the 2009 Personalized Medicine Conference: The Time is NowEndo Pharmaceuticals is rede�ning its position in the marketplace by embracing the evolution of healthcare and the urgent need for high-quality and cost-e�ective care. Our company is expanding to bring new therapies to patients, new treatment approaches to physicians and better outcomes to managed care providers. We strive to be the premier partner to healthcare professionals and payers by delivering an innovative suite of diagnostics, drugs, devices and clinical data to meet the needs of patients with a variety of conditions.

ExpandingOur Focus

Helping make personalized medicine a reality:

Enhanced Drug Safety/E�cacyWorking with the pharmaceutical industry from biomarker discovery through commercial launch to bring genetically targeted drugs to market

Outcome Improvement ProgramsProviding actionable, evidence-based information to physicians and their patients to help manage common disease states

Marker Discovery

AnalyticalTesting

ClinicalTrials

ClinicalTesting

©2009 Laboratory Corporation of America® Holdings All rights reserved. 7631-1009

ed DEnhanc a�cy/Eetafeug Srd D yac

tO

ing genetically taro brtker discbiomar

ing with the pharkorWed DEnhanc

t PI

oed drugs tgetnetically tarommerough cy thrervodisc

eutical industrmacth the phara�cy/Eetafeug Srd D

keto marcial launcher

omy frdustryac

help manage ction tmaorinf

viding acorPome IcutO

estommon disease stae csicians and their payo pht

-basede, evidenctionablecgort PemenvomprI

sots ttienpa

damsgr

7631-1009All rights reserved.Corporation of Laboratory 9©200

09Holdings®Americaon of

25

ENHANCED VISION, ADVANCED RESEARCHPOWER YOUR TRANSLATIONAL MEDICINE WITH INTEGRATED SCIENTIFIC INFORMATION:

• Biology• Chemistry• Pharmacology• Biomarkers• Clinical Trials

Stay focused on the next innovation with solutions from Thomson Reuters.

To learn more, visit go.thomsonreuters.com/translationalresearch

26

27

LABORATORY FORMOLECULAR MEDICINE

A diagnostics laboratorycreated by

Bringing genetics to medicinehttp://pcpgm.partners.org/LMM

28

The Partners HealthCare Center forPersonalized Genetic Medicine(PCPGM) was launched in 2001 as theHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics. Its new name was adoptedin late 2008 to reflect a heightenedfocus on translational issues related tomoving genetics and genomics intoclinical practice. Its purposes from itsfounding have been to promote genet-ics and genomics in research and clini-cal medicine and to help realize thepromise of personalized medicine byaccelerating the integration of geneticknowledge into clinical care through-out the Partners HealthCare System(PHS) and in healthcare nationally andglobally. PCPGM is accomplishing itsmission by supporting and facilitating:

• pursuing important discoveries thatwill enable advancing the knowledge of how genetics affects humanhealth and disease

• offering genetic-based diagnostictesting and developing new teststhrough a CLIA- and state-approvedLaboratory for Molecular Medicine

• developing an IT infrastructure tointegrate genetic and genomic datainto clinical decision support systems

• educating practicing clinicians,investigators, health careprofessionals

Personalized medicine is the ability todetermine an individual’s uniquemolecular characteristics and to usethose genetic distinctions to diagnosemore finely an individual’s disease,select treatments that increase thechances of a successful outcome andreduce possible adverse reactions.Personalized medicine also is the abili-ty to predict an individual’s susceptibil-ity to diseases and thus to try to shapesteps that may help avoid or reducethe extent to which an individual willexperience a disease.For personalized medicine to be a

fully functioning reality at the clinicallevel, certain elements are essential: anelectronic medical record, personalizedgenomic data available for clinical use,physician access to electronic decisionsupport tools, a personalized healthplan, personalized treatments, and per-sonal clinical information available forresearch use. Partners HealthCare hasmade a firm commitment to the princi-ples of personalized medicine and tothe importance of genetics andgenomics in delivering the best care ofpatients. PHS also has committed toensuring that the features above are orwill be available.The essential feature of the revolu-

tion in genetics and genomics hasbeen an explosion in the amount ofdata available for use in translationalresearch. This massive data profusion

has enhanced our ability to predictclinical phenotypes and to predict clini-cal outcomes on the basis of genomescale data. However, to be able to dothis sort of prediction investigatorsneed several tools. First, they need arobust bioinformatics infrastructurewith secure pipelines and robust algo-rithms for data cleaning and manipula-tion. Second, they need very strongbioinformatics platforms for dataanalysis and data management. Third,they need access to large numbers ofvery well phenotyped patients. Fourth,they need access to the genomic plat-forms to create genomic scale data onthese patients for prediction of clinicaloutcomes. Finally, they need novel sta-tistical and bioinformatics methods toanalyze these data for predictive medi-cine. PCPGM makes all of theseresources available to Partners investi-gators through a highly developedinfrastructure consisting of bioinfor-matics and genetic statistics; biosam-ple repository; core sequencing, geno-typing and GeneChip® and microarraylaboratories; and information technolo-gy services.

For more information aboutPCPGM, please visithttp://pcpgm.partners.org

Partners HealthCare Center for Personalized Genetic Medicine

Harvard Business School’s mission is to train business lead-ers in all industries. Healthcare, a $2 trillion industry, hasbecome one of the school’s key priorities. The HealthcareInitiative at HBS was launched in 2005 to bring together theextensive research, thought leadership, and interest in thebusiness and management of healthcare that exists at HBS.Healthcare research at HBS focuses on entrepreneurship,

innovation and disruption. Faculty and students seek tounderstand and identify new products, services and deliverymethods that will help to reshape the industry. HBS believesthis focus on “creative destruction” will result in business

models that offer the hope of improved outcomes, reducedcosts, streamlined systems, and enhanced services.Personalized medicine presents tremendous opportunities

in healthcare and has garnered much attention at HBS. Withits expertise in technology, commercialization, and businessmodel development, HBS can play a critical role in the wide-spread adoption of personalized medicine applications.

For more information about the HBS HealthcareInitiative, please visit www.hbs.edu/healthcare.

Harvard Business School

29

Wireless LoginLocate the wireless entry point on your device labeled “HMS Public.” Once connected, your browser will automaticallytake you to a Terms of Use page. Click on the Accept button to agree.

Lunch Table DiscussionsAttendees should remain at their tables following the luncheon for a discussion about one or more of the topics below.The assigned table chair should lead the discussion. If there are two co-chairs at one table, each should take equaltime to lead the discussion. The chair/co-chair or her/his designee will summarize the main points of the discussionand add this summary, limited to 200 words, to the conference website blog. Summaries should be added using adevice belonging to one of the table members and should be posted by 3:15 p.m. on Wednesday, November 18. Thesummary page should include the names and companies of those at the table who participated in the discussion.

1. Public Policy – What is the role of personalized medicine within the framework of current healthcare reform?

2. Comparative Effectiveness Research (CER) – What is the role of CER in personalized medicine?

3. Reimbursement – Who should take the lead – CMS, payers, consumers?

4. Consumers – What is the role of consumers in personalized medicine?

DIRECTIONS FOR TABLE DISCUSSION CHAIRS TO POST DISCUSSION SUMMARIES TO BLOGGo to www.personalizedmedicineconference.org/adminEnter Email: [table discussion chair’s email address]Enter Password: PMConf09Click Sign OnCheck the box to “I agree to these terms”Click ContinueClick on the Blog iconAt the top right of the screen, click the gray add a new entry buttonFor Category: November 18 Table DiscussionsFor Entry Name: Table [#] [topic] Discussion, e.g. Table 14 Public Policy DiscussionFor Entry, type the summary of your table discussion, limited to 200 words or fewerClick Add Entry“Table [#] [topic] Discussion blog added successfully” should show up in redTo confirm, click view next to your entryClick Sign off

Audience Response SystemWe will be using an audience response system during this year’s meeting in an effort to make the conference moreinteractive and inclusive of the audience. Please pick up a wireless keypad when you enter the amphitheater beforeeach session. During panels, moderators will pose questions for the audience, to which you should respond using thekeypad. Compiled results will be displayed promptly, which we hope will fuel further discussion. Keypads must bereturned at the end of each session. The system will only be used in the amphitheater and not in the lunchtime rooms.

30

Raju Kucherlapati, Ph.D., ChairPaul C. Cabot Professor of Genetics,Professor of MedicineHarvard Medical School

Edward Abrahams, Ph.D.Executive DirectorPersonalized Medicine Coalition

Mara G. AspinallPresident & CEOOn-Q-ity

Linda AveyFounderBrainstorm Research Foundation

M. Kathleen Behrens, Ph.D.FounderKEW Group

G. Steven BurrillCEOBurrill & Company

Brook ByersPartnerKleiner Perkins Caufield & Byers

Nadine Cohen, Ph.D.Head of Pharmacogenomics and SeniorResearch FellowJohnson & Johnson PharmaceuticalResearch and Development East Coastand Europe

Frank Douglas, Ph.D., M.D.PartnerAusten BioInnovation InstituteSenior Director, PureTech Ventures

Robert S. Epstein, M.D., M.S.Senior Vice President, Medical &Analytical Affairs & CMOMedco Health Solutions, Inc.

John P. Glaser, Ph.D.Vice President andChief Information OfficerPartners HealthCare System

Richard G. Hamermesh, DBAMBA Class of 1961 Professor ofManagement PracticeFaculty Chair, HBS Healthcare InitiativeHarvard Business School

Regina E. Herzlinger, D.B.A.Nancy R. McPherson Professor ofBusiness AdministrationHarvard Business School

Katherine Johansen, Ph.D.Senior Scientist, Genetics and MolecularMedicineAmerican Medical Association

Marcia A. KeanCEO, Feinstein Kean Healthcare

David KingPresident & CEOLaboratory Corporation of America

Mark LevinCo-FounderThird Rock Ventures LLC

Carol McCall, FSA, MAAVice President, Research andDevelopment, Humana

Jeffrey D. MillerManaging PartnerVersum Ventures

Samuel R. Nussbaum, M.D.Executive Vice President and ChiefMedical OfficerWellpoint, Inc.

Eiry W. Roberts, M.D.VP Lilly Research Labs - Autoimmunityand Transition PhaseEli Lilly and Company

Hakan Sakul, Ph.D.Senior Director and Global Head ofDiagnosticsTranslational and Molecular MedicineGroupWorldwide DevelopmentPfizer Global Research & Development

Sue SiegelPartnerMDV-Mohr Davidow Ventures

Scott Weiss, M.D., M.S.Interim Scientific Director, PartnersHealthCare Center for PersonalizedGenetic MedicineBrigham and Women’s HospitalChanning Laboratories

COMMITTEE MEMBERS EX OFFICIO

Alfred A. Blum, Jr.Chief Development OfficerPartners HealthCare Center forPersonalized Genetic Medicine

Janice LarsonDevelopment AssociatePartners HealthCare Center forPersonalized Genetic Medicine

Rebecca RehmProgram AssociatePartners HealthCare Center forPersonalized Genetic Medicine

Conference Organizing Committee

Partners HealthCare Centerfor Personalized GeneticMedicine Labs at 65Landsdowne Street,Cambridge

32 Design: Vergara DesignPhotography: Justin Knight Photography

Personalized Medicine:The Time is Now

Alfred A. Blum, Jr.Chief Development Officeraablum@partners.org

Janice LarsonDevelopment Associatejalarson@partners.org

Rebecca RehmProgram Associaterrehm@partners.org

Meini Sumbada ShinAdministrative Director

msumbadashin@partners.org

Conference staffPartners HealthCare Center for Personalized Genetic Medicine

Scott Weiss, M.D., M.S.Interim Scientific Director, Partners HealthCare Center for Personalized Genetic Medicine

Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital

SAVE THE DATE6th Annual Personalized Medicine Conference

November 17-19, 2010 *

* Conference will be either 17-18 or 18-19